news

Continuous bioprocessing market to achieve 23 percent CAGR

5
SHARES

Market research suggests the continuous bioprocessing market will value $348.9 million by 2027, driven by the rising demand for biopharmaceuticals.

Industrial bioreactor for microbial fermentation

According to a new report, the global continuous bioprocessing market should witness a 23 percent compound annual growth rate (CAGR) between 2021 and 2027, reaching a value of approximately $350 million.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The analysts found that the market growth is being driven by the rising demand for biopharmaceuticals, technological developments in continuous bioprocessing, new product launches and global initiatives supporting the adoption of biopharmaceuticals. They suggest that the shift towards industry (bioprocess) 4.0 in developing countries and the adoption of personalised medicine will present significant opportunities for market growth in the forecast period (2021-2027).

By product, filtrations systems and consumables was the largest market segment in 2020, with the demand for higher filter operation standards being a major factor supporting growth. The analysts report that a major development is that filter manufacturers are working to develop filtration technologies for continuous bioprocessing that can both separate and purify by combining the physical removal capabilities of filtration and size exclusion.

In terms of application, the R&D segment is expected to achieve the highest CAGR in the forecast period, as a result of COVID-19 related therapeutic and vaccine research, and the need for monoclonal antibody manufacturing to supply treatments for a variety of diseases. Additionally, the report suggests that R&D into cell and gene therapy will also drive growth in this segment. Facility expansions of contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs) will advance research in these areas and thus enhance market growth, according to the authors.

By end-user, the CROs and CDMOs segment is expected to expand the fastest over the next six years, with rising investment in contract manufacturing/research and the shift of CDMOs from batch to continuous manufacturing expected to drive the growth.

In 2020, North America commanded the largest share of the global continuous bioprocessing market, followed by Europe, Asia-Pacific, Latin America and the Middle East & Africa. The established healthcare system in North America, greater adoption of advanced technologies, growth in pharmaceutical R&D and presence of key players will help the region retain dominance in the forecast period.

Key players in the global continuous bioprocessing market include 3M, Cytiva, Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Repligen Corporation, Eppendorf AG, Applikon Biotechnology, Pall Corporation and Bionet.

Share via
Share via